Alkermes PLC (NASDAQ:ALKS) SVP James M. Frates sold 20,932 shares of the firm’s stock in a transaction dated Wednesday, November 8th. The stock was sold at an average price of $47.58, for a total transaction of $995,944.56. The transaction was disclosed in a legal filing with the SEC, which is accessible through this hyperlink.

Shares of Alkermes PLC (NASDAQ:ALKS) traded down $0.20 during midday trading on Friday, hitting $47.85. 1,285,195 shares of the company traded hands, compared to its average volume of 831,124. The company has a current ratio of 3.05, a quick ratio of 2.72 and a debt-to-equity ratio of 0.23. Alkermes PLC has a 12 month low of $46.80 and a 12 month high of $63.40.

Alkermes PLC (NASDAQ:ALKS) last issued its earnings results on Thursday, October 26th. The company reported $0.03 EPS for the quarter, topping the consensus estimate of ($0.01) by $0.04. Alkermes PLC had a negative net margin of 20.12% and a negative return on equity of 7.27%. The company had revenue of $217.40 million for the quarter, compared to the consensus estimate of $231.29 million. During the same period in the previous year, the firm earned ($0.09) earnings per share. The firm’s revenue for the quarter was up 20.6% on a year-over-year basis. analysts anticipate that Alkermes PLC will post -0.59 earnings per share for the current fiscal year.

COPYRIGHT VIOLATION NOTICE: “Alkermes PLC (ALKS) SVP James M. Frates Sells 20,932 Shares of Stock” was published by The Cerbat Gem and is owned by of The Cerbat Gem. If you are viewing this piece on another publication, it was illegally copied and republished in violation of U.S. and international copyright laws. The original version of this piece can be viewed at https://www.thecerbatgem.com/2017/11/10/alkermes-plc-alks-svp-james-m-frates-sells-20932-shares-of-stock-3.html.

A number of research firms recently issued reports on ALKS. Zacks Investment Research upgraded shares of Alkermes PLC from a “sell” rating to a “hold” rating in a report on Wednesday, August 2nd. ValuEngine downgraded shares of Alkermes PLC from a “hold” rating to a “sell” rating in a report on Thursday, July 27th. Barclays PLC downgraded shares of Alkermes PLC from an “overweight” rating to an “equal weight” rating and decreased their price objective for the stock from $66.00 to $50.00 in a report on Monday, October 16th. J P Morgan Chase & Co set a $78.00 price objective on shares of Alkermes PLC and gave the stock a “buy” rating in a report on Friday, October 27th. Finally, UBS AG set a $54.00 price objective on shares of Alkermes PLC and gave the stock a “hold” rating in a report on Friday, October 27th. Two analysts have rated the stock with a sell rating, seven have given a hold rating and five have issued a buy rating to the stock. The company presently has an average rating of “Hold” and a consensus price target of $63.55.

Hedge funds and other institutional investors have recently modified their holdings of the stock. Teachers Advisors LLC increased its position in Alkermes PLC by 11.8% during the 1st quarter. Teachers Advisors LLC now owns 155,311 shares of the company’s stock valued at $9,086,000 after purchasing an additional 16,354 shares during the period. PNC Financial Services Group Inc. increased its position in Alkermes PLC by 0.6% during the 1st quarter. PNC Financial Services Group Inc. now owns 7,104 shares of the company’s stock valued at $415,000 after purchasing an additional 42 shares during the period. Dimensional Fund Advisors LP increased its position in Alkermes PLC by 1.5% during the 1st quarter. Dimensional Fund Advisors LP now owns 194,531 shares of the company’s stock valued at $11,381,000 after purchasing an additional 2,891 shares during the period. Renaissance Technologies LLC purchased a new position in Alkermes PLC during the 1st quarter valued at $7,306,000. Finally, Capstone Asset Management Co. increased its position in Alkermes PLC by 2.6% during the 2nd quarter. Capstone Asset Management Co. now owns 6,755 shares of the company’s stock valued at $392,000 after purchasing an additional 170 shares during the period. 98.19% of the stock is currently owned by institutional investors.

About Alkermes PLC

Alkermes plc is a biopharmaceutical company. The Company is engaged in the researching, developing and commercializing pharmaceutical products that are designed to address medical needs of patients in therapeutic areas. The Company has a portfolio of marketed drug products and a clinical pipeline of products that address central nervous system (CNS) disorders, such as schizophrenia, depression, addiction and multiple sclerosis (MS).

Insider Buying and Selling by Quarter for Alkermes PLC (NASDAQ:ALKS)

Receive News & Stock Ratings for Alkermes PLC Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Alkermes PLC and related stocks with our FREE daily email newsletter.